Bicara Therapeutics(BCAX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Bicara Therapeutics
BCAX.US
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
1.813 T
BCAX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

    Market Beat·
    US
    BCAX
    +3.84%
    US
    BBH
    +0.68%
    Market Beat·
    US
    BCAX
    +3.84%
    US
    BBH
    +0.68%

    Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

    Tip Ranks·
    US
    BCAX
    +3.84%
    Tip Ranks·
    US
    BCAX
    +3.84%

    Bicara Therapeutics hires Replimune, Sanofi alum as CCO

    Fiercepharma·
    US
    REPL
    -6.19%
    US
    SNY
    +0.02%
    US
    BCAX
    +3.84%
    Fiercepharma·
    US
    REPL
    -6.19%
    US
    SNY
    +0.02%
    US
    BCAX
    +3.84%

    Bicara Records $56 Mln Loss In Q1; Provides Updates On Ficerafusp Alfa Trials

    nasdaq·
    US
    BCAX
    +3.84%
    nasdaq·
    US
    BCAX
    +3.84%

    Bicara Therapeutics shares are trading lower. The company reported worse-than-expected Q1 EPS results.

    benzinga_article·
    US
    BCAX
    +3.84%
    US
    XBI
    -0.69%
    US
    FBT
    +0.54%
    benzinga_article·
    US
    BCAX
    +3.84%
    US
    XBI
    -0.69%
    US
    FBT
    +0.54%
    © 2026 Longbridge｜Disclaimer